Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

World Chemotherapy Induced Neutropenia (CIN) Market Insights, Epidemiology and Market Forecasts 2017-2023 - Research and Markets

Research and Markets
Posted on: 24 Aug 17

The "Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology and Market Forecast - 2023" drug pipeline has been added to Research and Markets' offering.

Chemotherapy Induced Neutropenia (CIN) - Market Insights, Epidemiology and Market Forecast - 2023 provides an overview of the disease and global market trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW).

The report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer indications till 2023.

The report covers the number of patients for 10 cancer indications (i.e., Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers.

Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to research, the worldwide CIN market is estimated to increase at a CAGR of 3.37% for the forecast period i.e., 2013-2023.

Key Topics Covered:

  1. Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance
  2. Global Market Size of CIN in 2016
  3. Global Market Size of CIN in 2023
  4. Chemotherapy Induced Neutropenia (CIN)
  5. Overview
  6. Causes of Neutropenia
  7. Common cycle of chemotherapy-related neutropenia
  8. Signs and symptoms
  9. Risk Factors
  10. Severity and Grades of Neutropenia
  11. Pathophysiology/Mechanisms of action
  12. Diagnosis
  13. Epidemiology and Patient Population
  14. Assumptions and Caveats
  15. NCCN Guidelines for Chemotherapy Induced Febrile Neutropenia
  16. Evaluation prior to First Chemotherapy Cycle
  17. Overall Febrile Neutropenia Risk
  18. Evaluation Prior to Second and Subsequent Chemotherapy
  19. Therapeutic use of Granulocyte-colony stimulating factor (G-CSF) for Febrile Neutropenia
  20. European Organisation for Research and Treatment of Cancer (EORTC)

Marketed Drugs

  • Neupogen: Amgen
  • Neulasta: Amgen
  • Zarxio: Sandoz
  • Granix: Teva Pharmaceuticals
  • Lonquex: Teva Pharmaceuticals
  • Tevagrastim: Teva Pharmaceuticals
  • Filgrastim BS Injection: Fuji Pharma Co., Ltd.

Biologicals/Biosimilar Pipeline

  • Plinabulin: BeyondSpring Pharmaceuticals, Inc.
  • Rolontis: Spectrum Pharmaceuticals, Inc.
  • CHS-1701: Coherus Biosciences
  • Myelo001: Myelo Therapeutics GmbH

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 24/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.